Compare Mondaycom Ltd (MNDY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Mondaycom Ltd trades at $88.68 (market cap $3.76B), while Vertex Pharmaceuticals Incorporated trades at $507.41 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 33.9× Mondaycom Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MNDY | VRTX | |
|---|---|---|
Market Cap | $3.76B | $127.55B |
Volume | 836,200 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $205.24 | $557.96 |
52-Week Low | $58.81 | $407.37 |
Typical Hold Time | 16 Days | 120 Days |
Enterprise Value | $2.92B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) is trading at $89.50, up 7.17% with strong momentum following consecutive earnings beats. The stock shows bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company maintains robust revenue growth ($1.23B in 2025) and high gross margins (88.74%), though valuation multiples remain elevated with P/E at 37.69. Recent news highlights strong enterprise client growth and AI integration initiatives at the upcoming Elevate '26 conference.
The outlook remains positive with 65% analyst buy ratings and a $108.64 consensus target, representing 21% upside. Key risks include competitive pressure from Meta's enterprise push and elevated valuation sensitivity. Earnings momentum and enterprise expansion provide catalysts, but investors should monitor Q3 2026 results against the $1.37 EPS expectation for sustained growth validation.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
